To be compliant for NASDAQ I would say it is inevitable.
Previously NASDAQ Granted Extension To Immune Pharmaceuticals Inc. To Regain Compliance With Requirements Under NASDAQ Listing Rule 5810(c)(3)
Barring any substantial partnerships or news expect anywhere from
1/2 to 1/25 reverse split sometime in December.
Jul 6 16
On July 6, 2016, Immune Pharmaceuticals Inc. received a notification from the Listing Qualifications Department of The NASDAQ Stock Market LLC (NASDAQ) indicating that the company had been granted an additional 180 calendar day extension, or until January 3, 2017, to regain compliance with the requirements under NASDAQ Listing Rule 5810(c)(3). The notification stated that Extension determination was based on the company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market, with the exception of the bid price requirement. The notification has no immediate effect on the NASDAQ listing or trading of the company’s common stock. As previously reported on a Current Report on Form 8-K dated January 11, 2016, the company had received a prior notification from NASDAQ, dated January 5, 2016, indicating that the company was not in compliance with the Rule because the minimum bid price of the company’s common stock on the NASDAQ Capital Market had closed below $1.00 per share for 30 consecutive business days. In the event the company does not regain compliance with the Rule by January 3, 2017, NASDAQ will notify the company that its common stock will be delisted from the NASDAQ Capital Market, unless the company requests a hearing before a NASDAQ Hearings Panel. This information is being provided solely to comply with NASDAQ Listing Rules requiring public announcement of the company’s receipt of the letter from NASDAQ.
